Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437136 | 0.78 | ALDH1A1 (0.60) | MAPTGAASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6359414 | 0.72 | MAPT (0.59) | MAPTGAASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL678481 | 0.71 | ALDH1A1 (0.52) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10870706 | 0.71 | MAOA (0.60) | MAPTSMN1; SMN2ALDH1A1POLBMEN1 | |
| SCHEMBL6807417 | 0.70 | KEAP1 (0.54) | MAPTGAASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL600330 | 0.69 | ALDH1A1 (0.85) | MAPTGAASMN1; SMN2ALDH1A1KEAP1 | |
| SCHEMBL31276140 | 0.69 | ALDH1A1 (0.85) | MAPTGAASMN1; SMN2ALDH1A1KEAP1 | |
| SCHEMBL30808237 | 0.69 | ALDH1A1 (0.85) | MAPTGAASMN1; SMN2ALDH1A1KEAP1 | |
| SCHEMBL20271919 | 0.68 | MAOA (0.69) | MAPTGAASMN1; SMN2ALDH1A1KEAP1 | |
| SCHEMBL4586925 | 0.68 | MAPT (0.56) | MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | MAPT 844/4885GAA 441/4885SMN1; SMN2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.